

From invention to innovation

APPLICATIONS

- Treatment of solid tumors, in particular in colon, lung, ovaria, uterus

DEVELOPMENT PHASE

- Hit to lead optimization
- *In vitro* validation of the lead in 24 cancer cell lines
- *In vivo* proof of concept with the lead compound in several solid tumors

INTELLECTUAL PROPERTY

Patent applications in Australia, Canada, China, Europe, United States of America, Japan, filed on January 2015. Examination in progress.

CONTACT

Mail : eae@idfinnov.com

Phone : + 33 (0)1 80 05 65 05

NOVEL ANTITUMORAL SMALL MOLECULE


A new anti-proliferative and anti-vascular class of chemical agents for solid tumor treatment

Cancer ■ Anti-proliferative ■ Anti-Vascular ■ Tumor Therapy ■
Small molecule

PRESENTATION

There is a need for new, efficacious anticancer agents associated with increased response rates and with limited and manageable toxicity.

The present offer proposes a **novel chemical compound with anti-proliferative and anti-vascular properties validated *in vitro* and *in vivo***. This compound has shown high efficient anti-cancer potency in *in vitro* models using **24 cancer cell lines** (some of them being resistant to chemotherapies). *In vivo*, this compound has shown a tumor volume reduction of **80-95% on lung and colon murine tumors with no major identified side effects**.



Administration of the lead compound on colon 26 tumors in mice leads to a slower growth of tumor size © Sylviane Giorgi-Renault

COMPETITIVE ADVANTAGES

- New chemical entity
- Water soluble, stable and easy to synthesize
- High efficiency in 24 different *in vitro* cell lines including multidrug resistant ones
- Better efficacy than the anti-vascular comparator combretastatin CA4